Abstract

NIGORA AKESHOVA, GAUKHAR KURMANOVA, ARZU & 1052;AMUTOVA, ALMAGUL KURMANOVA, IKILAS MOLDALIEV

Summary. A number of clinical and population-based studies have shown a link between the development of insulin resistance and type 2 diabetes mellitus and hepatitis C.Purpose of research:to study the frequency of type 2 diabetes mellitus and its course in patients with chronic viral hepatitis C and B during antiviral therapy.Material and methods:213 patients (164 with CVH C, 34 with CVH B and 15 with CVH B + C) were examined before and in the course of treatment. All patients received standard antiviral therapy. In patients with type 2 diabetes, the level of fastingglycemiawas determined daily in the first 8-12 weeks of treatment. The level of glycemia was determined at the laboratory at least once every 2 weeks. Glycated hemoglobin was determined every 3 months during treatment and another 6 months after completion of the antiviral therapy.Results: In the group of patients with CVH C, type 2 diabetes mellitus occurred 2 times more often (13.4%) than in groups with CVH B (6.1%) with a reliability of p <0.01. With HCV genotype 3 is 2.5 times more often than with genotype 1 (p <0.001). Among patients, type 2 diabetes is 2.5 times more often men than women (p <0.01).Upon reaching an early virological response in 77.3% of patients, the level of glycemia returned to normal. The correlation coefficient between the achievement of a full virological response (negative PCR results on HCV RNA) and the normalization of the level of glycemia was 0.75. Glycemia control was maintained for 6 months after the completion of the antiviral therapy in the background of a persistent virological response.Conclusions:The presence of diabetes is the basis for screening for HCV, regardless of other factors. 75-77% of type 2 diabetes mellitus in the cohort of patients with CVH C is possibly virus-associated. Treatment of HCV infection can lead to a cure for type 2 diabetes mellitus in this category of patients.